Everest Medicines

News

28 2023/02

Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility
10 2023/02

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary IgA Nephropathy
18 2023/01

Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
03 2023/01

Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
30 2022/12

Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
30 2022/12

Everest Medicines to Hold New Corporate Strategy Conference Calls
28 2022/12

Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma
22 2022/12

Everest Medicines’ Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
15 2022/12

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
28 2022/11

Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy
15 2022/11

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy
19 2022/10

Everest Medicines Announces Partner Providence Reports Positive Top-Line Data from Phase 2 Primary Immunization Trial for mRNA COVID-19 Vaccine Candidate in Adults

Copyright Everest Medicines 2020 云顶药业（苏州）有限公司苏ICP备20038571号 | Terms of Use | Privacy Policy | Disclaimers

沪公网安备 31010602006477号